FAGR Stock Overview
Fagron NV, a pharmaceutical compounding company, provides personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients.
Price History & Performance
|Historical stock prices|
|Current Share Price||€17.04|
|52 Week High||€20.08|
|52 Week Low||€13.11|
|1 Month Change||-2.96%|
|3 Month Change||12.55%|
|1 Year Change||-8.68%|
|3 Year Change||-0.35%|
|5 Year Change||44.65%|
|Change since IPO||69.22%|
Recent News & Updates
Fagron (EBR:FAGR) Is Paying Out A Larger Dividend Than Last Year
Fagron NV ( EBR:FAGR ) will increase its dividend on the 18th of May to €0.14. Despite this raise, the dividend yield...
|FAGR||BE Healthcare||BE Market|
Return vs Industry: FAGR exceeded the Belgian Healthcare industry which returned -18.9% over the past year.
Return vs Market: FAGR underperformed the Belgian Market which returned -4.4% over the past year.
|FAGR Average Weekly Movement||4.6%|
|Healthcare Industry Average Movement||5.2%|
|Market Average Movement||4.8%|
|10% most volatile stocks in BE Market||7.8%|
|10% least volatile stocks in BE Market||2.8%|
Stable Share Price: FAGR is not significantly more volatile than the rest of Belgian stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: FAGR's weekly volatility (5%) has been stable over the past year.
About the Company
Fagron NV, a pharmaceutical compounding company, provides personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients. It prepares personalized ready-to-use medication in its sterile and non-sterile compounding facilities. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding.
Fagron Fundamentals Summary
|FAGR fundamental statistics|
Is FAGR overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|FAGR income statement (TTM)|
|Cost of Revenue||€326.31m|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
Aug 04, 2022
|Earnings per share (EPS)||0.84|
|Net Profit Margin||10.63%|
How did FAGR perform over the long term?See historical performance and comparison
1.2%Current Dividend Yield
Is Fagron undervalued compared to its fair value and its price relative to the market?
Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: FAGR (€17.04) is trading below our estimate of fair value (€37.16)
Significantly Below Fair Value: FAGR is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: FAGR is poor value based on its Price-To-Earnings Ratio (20.4x) compared to the European Healthcare industry average (18.9x).
PE vs Market: FAGR is poor value based on its Price-To-Earnings Ratio (20.4x) compared to the Belgian market (11.3x).
Price to Earnings Growth Ratio
PEG Ratio: FAGR is poor value based on its PEG Ratio (1.7x)
Price to Book Ratio
PB vs Industry: FAGR is overvalued based on its Price-To-Book Ratio (3.9x) compared to the XE Healthcare industry average (2x).
How is Fagron forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: FAGR's forecast earnings growth (12.2% per year) is above the savings rate (1.1%).
Earnings vs Market: FAGR's earnings (12.2% per year) are forecast to grow slower than the Belgian market (15.4% per year).
High Growth Earnings: FAGR's earnings are forecast to grow, but not significantly.
Revenue vs Market: FAGR's revenue (8.4% per year) is forecast to grow faster than the Belgian market (1% per year).
High Growth Revenue: FAGR's revenue (8.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: FAGR's Return on Equity is forecast to be low in 3 years time (18.6%).
How has Fagron performed over the past 5 years?
Past Performance Score2/6
Past Performance Score 2/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: FAGR has high quality earnings.
Growing Profit Margin: FAGR's current net profit margins (10.6%) are lower than last year (10.7%).
Past Earnings Growth Analysis
Earnings Trend: FAGR has become profitable over the past 5 years, growing earnings by 29.7% per year.
Accelerating Growth: FAGR's earnings growth over the past year (2.4%) is below its 5-year average (29.7% per year).
Earnings vs Industry: FAGR earnings growth over the past year (2.4%) underperformed the Healthcare industry 44.8%.
Return on Equity
High ROE: FAGR's Return on Equity (18.9%) is considered low.
How is Fagron's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: FAGR's short term assets (€233.7M) exceed its short term liabilities (€145.1M).
Long Term Liabilities: FAGR's short term assets (€233.7M) do not cover its long term liabilities (€329.9M).
Debt to Equity History and Analysis
Debt Level: FAGR's net debt to equity ratio (69.7%) is considered high.
Reducing Debt: FAGR's debt to equity ratio has reduced from 384.7% to 91.4% over the past 5 years.
Debt Coverage: FAGR's debt is well covered by operating cash flow (26.4%).
Interest Coverage: FAGR's interest payments on its debt are well covered by EBIT (13.2x coverage).
What is Fagron current dividend yield, its reliability and sustainability?
Dividend Score 2/6
Future Dividend Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: FAGR's dividend (1.17%) isn’t notable compared to the bottom 25% of dividend payers in the Belgian market (1.77%).
High Dividend: FAGR's dividend (1.17%) is low compared to the top 25% of dividend payers in the Belgian market (5.78%).
Stability and Growth of Payments
Stable Dividend: FAGR's dividend payments have been volatile in the past 10 years.
Growing Dividend: FAGR's dividend payments have fallen over the past 10 years.
Earnings Payout to Shareholders
Earnings Coverage: With its low payout ratio (23.8%), FAGR's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonably low cash payout ratio (25.3%), FAGR's dividend payments are well covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Rafael Padilla (43 yo)
Mr. Rafael Padilla has been Chief Executive Officer at Fagron NV since November 27, 2017 and served as its Area General Manager of South America and Southern Europe since October 25, 2016. Mr. Padilla serv...
CEO Compensation Analysis
Compensation vs Market: Rafael's total compensation ($USD951.11K) is above average for companies of similar size in the Belgian market ($USD588.79K).
Compensation vs Earnings: Rafael's compensation has been consistent with company performance over the past year.
Experienced Management: FAGR's management team is considered experienced (4.4 years average tenure).
Experienced Board: FAGR's board of directors are considered experienced (4.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Fagron NV's employee growth, exchange listings and data sources
- Name: Fagron NV
- Ticker: FAGR
- Exchange: ENXTBR
- Founded: 1990
- Industry: Health Care Distributors
- Sector: Healthcare
- Implied Market Cap: €1.241b
- Shares outstanding: 72.86m
- Website: https://www.fagron.com
Number of Employees
- Fagron NV
- Venecoweg 20A
- East Flanders
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/27 00:00|
|End of Day Share Price||2022/05/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.